LCTX Lineage Cell Therapeutics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: LCTX
Price (delayed)
$1.82
Market cap
$415.61M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.18
Enterprise value
$375.49M
Relative Growth:
Rel. Growth:
50
Relative Strength:
Rel. Strength:
97
Relative Valuation:
Rel. Valuation:
5
Relative Profitability:
Rel. Profitability:
18
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage's programs are based on its robust proprietary cell-based therapy platform and associated in-house
Highlights
The gross profit has soared by 89% YoY and by 15% from the previous quarter
The revenue has soared by 76% YoY and by 14% from the previous quarter
The company's net income has shrunk by 152% QoQ and by 69% YoY
LCTX's EPS has dropped by 125% since the previous quarter and by 38% year-on-year
Key stats
What are the main financial stats of LCTX
Market
Valuations
Earnings
Shares outstanding
228.36M
Market cap
$415.61M
Enterprise value
$375.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.59
Price to sales (P/S)
38.08
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.4
Revenue
$10.91M
Gross profit
$10.65M
Operating income
-$35.24M
Net income
-$40.91M
EBIT
-$40.91M
EBITDA
-$40.28M
Free cash flow
-$23.15M
Per share
Balance sheet
Liquidity
EPS
-$0.18
EPS diluted
-$0.18
Free cash flow per share
-$0.1
Book value per share
$0.21
Revenue per share
$0.05
TBVPS
$0.21
Total assets
$90.8M
Total liabilities
$43.69M
Debt
$2.15M
Equity
$48.39M
Working capital
$33.09M
Debt to equity
0.04
Current ratio
4.08
Quick ratio
3.96
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
-369.1%
Gross margin
97.6%
Net margin
-374.8%
Operating margin
-322.8%
Return on assets
-39.7%
Return on equity
-60.2%
Return on invested capital
N/A
Return on capital employed
-51.1%
Return on sales
-374.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LCTX stock price
How has the Lineage Cell Therapeutics stock price performed over time
Intraday
1.11%
1 week
6.43%
1 month
7.69%
1 year
115.51%
YTD
262.19%
QTD
7.69%
Financial performance
How have Lineage Cell Therapeutics's revenue and profit performed over time
Revenue
$10.91M
Gross profit
$10.65M
Operating income
-$35.24M
Net income
-$40.91M
Gross margin
97.6%
Net margin
-374.8%
The company's net income has shrunk by 152% QoQ and by 69% YoY
The net margin has plunged by 121% from the previous quarter but it has grown by 4.1% YoY
The gross profit has soared by 89% YoY and by 15% from the previous quarter
The revenue has soared by 76% YoY and by 14% from the previous quarter
Price vs fundamentals
How does LCTX's price correlate with its fundamentals
Growth
What is Lineage Cell Therapeutics's growth rate over time
Valuation
What is Lineage Cell Therapeutics stock price valuation
P/E
N/A
P/B
8.59
P/S
38.08
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.4
LCTX's EPS has dropped by 125% since the previous quarter and by 38% year-on-year
LCTX's P/B is 177% above its 5-year quarterly average of 3.1
LCTX's equity is down by 39% QoQ and by 29% YoY
LCTX's price to sales (P/S) is 154% more than its last 4 quarters average of 15.0 but 35% less than its 5-year quarterly average of 58.9
The revenue has soared by 76% YoY and by 14% from the previous quarter
Efficiency
How efficient is Lineage Cell Therapeutics business performance
LCTX's return on equity has dropped by 171% since the previous quarter and by 70% year-on-year
Lineage Cell Therapeutics's ROA has plunged by 159% from the previous quarter and by 72% YoY
LCTX's ROS has dropped by 121% since the previous quarter but it is up by 4.1% year-on-year
Dividends
What is LCTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LCTX.
Financial health
How did Lineage Cell Therapeutics financials performed over time
LCTX's total assets is 108% greater than its total liabilities
Lineage Cell Therapeutics's quick ratio has surged by 56% YoY and by 8% QoQ
The current ratio has surged by 55% year-on-year and by 7% since the previous quarter
The debt is 96% less than the equity
LCTX's equity is down by 39% QoQ and by 29% YoY
The debt to equity has grown by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.